Thanks, fourth solid morning, operational feeding for anchored strong continued to quarter results us our and of year financial you review the thank Scott. fourth for franchise. everyone, and We delivered our full by XXXX. a Good enteral performance quarter joining and
a We milestone of of business is with X, in to final October process. also the our transformation asset the our key related our completed This XXXX. completion obligations X-year sale respiratory health transfers on
recovering nonopioid in clinically patients postoperative Separately, and DOJ are our in pain. million received enteral medication the to our which recovery management to chronic or notification patients that we and served portfolio, need, with deferred proven with January, from have our support solutions, through over pleased our we those have conditions pain in agreement. feeding which pain essential we regards delivery Additionally, for XXXX from and commitments to nutrition those prosecution X met deliver therapies provide
decision approximately were transformation meet fourth impact sales effects to revenue were for organic ago. continuing return to X% did $XXX highlights. and year discontinue compared the operations Sales portfolio a strategic quarter Switching by during of from to that foreign our our priority, million, streams financial the the specified exchange adjusted up criteria of not
For generated per earnings SG&A percentage and adjusted million share adjusted from the nearly XX% a with margins XX.X%. $X.XX of of continuing quarter, revenue we diluted just of of and operations of adjusted gross EBITDA shy as $XX
Our its reporting fourth value that of quarter an carrying results million below assessment approximately fair GAAP based unit charge the was value. impairment company single our a upon include noncash $XXX of
full just compared operations effects million. For the not sales our our to continuing discontinue and the year, from were noted, year as exchange X.X% sales organic to criteria, return the foreign increased that earlier our I a strategic meet decision of $XXX Adjusted revenue ago. streams impact approximately did of for
We diluted to margin. point increase and XX% $X.XX, approximately year $XXX of or basis delivered adjusted earnings adjusted compared a expansion from the per operations EBITDA of XXX of million continuing almost share prior
XX SG&A improvement primarily as by compared were full percentage cost driven revenue initiatives with year the an process a gross XX.X%, year, XX%, year. And was transformation For the This basis business flat a of margins ago. of adjusted and was prior to improvements. points
strategic our this goals, our over progress we've performance are uneven I'll past our in against transformation our progress priorities. broader steady some few a in overall made with strengthened has ability had to we transformation execution the deliver XX minutes. While which the discuss months of and year, we on The our pleased each
liquidity. Now turning to and our financial position
on $XXX of hand us outstanding million of December strategic cash with Our million with balance remains as XX. of continues and provide strong $XXX sheet and to flexibility debt
$XX over weeks further of position approximately currently financial million of debt $XX our million. net improved early the in as and have cash We have XXXX of we
of the $XX income. This of During $XX $X.X we million cash an increase of $XX receivable that included of compared million interest the million flow, year. tax almost almost collection million year's previous an free free included the generated to year, cash flow
have capital returns we a allocation and From continue align that deploy M&A also opportunistic pursue we'll and standpoint, share for strategic as actively with previously repurchases. we shared, opportunities our to criteria, capital
minutes the at quarter Now I'll discussing results spend the category next level. few fourth product our
our above-market feeding feeding. This term, in term short growing organically double-digit enteral deliver almost to sustained continues reaffirming versus of capturing prior was business opportunities long results, America and advantage portfolio the as XX% to competitor's we from strong #X supported NeoMed ENFit neonatal Our continue year. by position line in for backorder. a product demand take conversions North which our also growth, while
During benefited partner. a from international OEM the also order we through fourth meaningful quarter, an
As levels business cycle. during the feeding we quarter but legacy Demand We expansion. quarters next growing with the our the few we product foundation growth XXXX dynamics commercial product global for adoption the execution, core deliver us overall a anticipate and have signaled, enter above our believe to enteral previous portfolio market at still for growth late remained year. further in compared the innovations for mid-single-digit fourth our for lower market provide of to stages these previously over line enteral ENFit market feeding NeoMed healthy, we as
the our this management quarter sales low-margin for pain products. X% down recovery strategic foreign certain and low-growth, of announced our discontinue previously to to excluding Normalized decision approximately exchange turning organic impact Now were portfolio. and
reimbursement implementation Act from while compared with business, by down of with improved afforded postsurgical pain hospitals and growing provides pain to a portfolio combined surgical our third overall rebounded to relief. caregivers weaker the no options sequentially. ON-Q ambIT nonopioid performance. administer quarter pain year, decision prior Our the XX% The
in this patient product better ambIT We our through offerings. to excited participate and are ON-Q care line
procedural more XXXX. Additionally, post to growing each XX% which shift our results, capitalized the to in ASC ambIT quarter the on product, excellent has than continues of
previous the quarter pain to Our high single-digit interventional or year. compared business, posted IVP this growth
capturing lines. Semtech product Trident our see within to momentum higher sales. continue our volumes, We IBP and generator especially in procedural
renewed productivity our the and increasing and outcomes. deployed fully ASC new credit structure strategy sales of our supporting these We
leveraging offering transaction tailwinds line countries, and progress expectations. in internationally, Additionally, the continues encouraged months internal our our acquired the exceed product of several XX Kingdom Diros reimbursement we ago, are Trident Japan. United growth by in COOLIEF to the including
U.S. on market with capitalizing to our accounts are technology. We XXX over successful Trident launch having converted our
our to moving Game offering. Now Ready
in our the As noted Game we the our fourth fourth last a portfolio XXXX. quarter particularly during quarter, call, decline in from anticipated we experienced given Ready strong
orthopedic fourth actual direct line high-level cash with the pay as some revenue of care, and expected, direct on in of continue deliver teams, X However, opportunities customers. to quarters was with quarter we first XXXX sales as in the sites sports
portfolio XXXX HA down Finally, our quarters' was full year. with slowing consistent sequentially for and forecasted aligns X our in decrease year-over-year, anticipated for results. the portfolio, the revenue while XX% in revenue was prior with of previously our HA HA off our
the segment. execute volume share in HA and we X to As progress strategies shot we grow categories, actively seeing X are the X shop in
X-shot pressure to pricing offsetting challenge, growth. in However, a share our continues present the overall offering
IVP XXXX, some and the across saw Although we had that delivered mid-single-digit we growth. are in throughout mixed organic year businesses management this progress results Game we Ready and our the recovery by encouraged pain portfolio
PM&R the across following portfolio in the expect we ahead, XXXX. Looking
tailwinds surgical just products see organic continuing pricing continuing gains, Our and years with HA make as our I of noted. IVP reversing to Game line and to our pain pressure, Ready Pain outcomes the negative businesses product Act No
XXXX Now and transformation moving priorities to our to XXXX efforts.
product to we our measures on As go-to-market portfolio our categories where profiles improve to key a capital to we and organization, enhance of commercially cost priorities profitability are our have and management These margin the our ability continuing attractive our allocation to have enhance to reminder, meaningfully additional meaningfully taking focus path X profile. transforming execution designed operating ROIC. optimizing win our efficient priorities improve financial and and strategically
expect divestiture We We business, important gains of from to fourth distribution following the and our continue America North remaining executed We health continue expected Trident our greater go-to-market quarter. to technology, share during for transformation consistent feeding AirLife our assets benefiting exiting are early us agreements. growth with allowing our generator early XXXX. that we procedural gains we to record included business on XXXX, maintained completed support against volume sales conveyance achieve wins conversion these that enteral into growth globally. strategy will during to strong our of in IVP priorities, and global Mexican respiratory business progress the all October than make certain which in in in growth the realized the ongoing XX%
establishment continued business drive progress also of our third-party providers programs our better in us will portfolio, new data streamline to product the to innovation and solutions allow identify AI customers, and targeting efficiencies, which with We assist utilize service decision-making. efficiency of
for and year, agreement we company-wide our We us and prosecution appropriately will throughout to with throughout with programs. deferred identified the DOJ levels our our discipline executed to further January. maintained XXXX. also acquisitions current And We be positioned the cost allow M&A in management leverage relation exited
these you off making transformation are expect will changes our have businesses. has this initiatives primarily growth that made provide XXXX run as tempered we June inconsistent businesses solid of PM&R Investor As well transparency Day the top To business. our and outcomes strategies line the mirror go-to-market financial know, our reporting we we around and to changes enable transformation we journey margin how transformation our the kicked benefit progress. our results, profiles at been that will full full of to as us efforts of challenge, and actively improve Nonetheless, our our address realize by more in
clear experience company's growth and We priorities focus deliver margin all business are to improve impact priorities capitalize positively have processes, refined the operating expansion. to our and on customer strategic organizational opportunities ensure and
business, X first we approach start segments. To will we how the align with quarter reporting starting in of will under XXXX, the manage operating this
feeding renamed enteral will as low-profile our our tubes. MIC-KEY, segment. enteral segment include feeding our portfolio, Specialty featuring Nutrition First, Systems This will feeding our portfolio long-term be
And short-term our placement, feeding tubes includes Our pediatric X and finally, our solutions. NeoMed feeding feeding nasogastric encompassing CORGRIP our system. tube NICU CORFLO our neonatal CORTRAK which Retention portfolio, guided our portfolio,
enteral to leading Systems products responds integrated to a portfolio need Nutrition from nutrition a bold specialty name feeding Specialty that our and for simplified ecosystem. expand nutrition captures The enteral the to portfolio patient-preferred our vision life-sustaining feeding
RFA Next, with Corporate single pumps our in Conventional our and electronic solution pain combined Elastomeric lines recovery our Other reported include segment. and along hyaluronic Timed will On-Q solution, injections intravenous our interventional This offering. cold pain pumps, and our and a pain combined ambIT and Semtech finally, acid It pumps pain offering, and and will our be also our and pain ablation RFA management will will solution. our Cooled recovery surgical management our pain And featuring featuring Trident frequency RFA into our therapy be Game Ready portfolio, segment. infusion product compression portfolios X-tier radio segment and COOLIEF include
will our transparency this believe highlight the we recovery of segments. noted, systems and and financial nutrition pain As management profiles specialty
capital across will evaluate importantly, More as optimize this guide stronger our segments. investment returns internal each of helping us opportunities we and allocation ROIC achieve decisions.
our XXXX Now outlook. turning to
Our XXXX and a guidance for market reflects factors, macroeconomic of as our product well tariffs. challenging categories other as global currency like headwinds some environment
$XXX flat the of to improvement organic to to factors, net segment million sales in pause due segment growth. executing Pain a margin deliver targets. temporary our Management strategy, Accordingly, Nutrition stated committed previously and million. With anticipate Systems range remain to organically, we in digits our single-digit While to our we and growing margin this achieving Specialty expect Recovery our these mid-single low $XXX expected year long-term we
of results decline anticipated dollar. speculate basis downstream line are as near over currency we Finally, on points well And this of of on approximately are from of tariff are effects closely customers. future you earnings or potential XXX and support our our manufacturing between we To exchange for currency foreign landscape know, currently the revenue XX%. the reported expected will and assuming we don't due These therefore, year. reiterate, adjusted sourcing movements, $X.XX. in Other are, current monitoring as the levels Corporate Mexico, Separately, Canada to and any as to duration very rates $X.XX headwinds top and strengthening and China reflects evolving aware, guidance share on the diluted U.S. is the you as per segment
While an on on we continued potential await to mitigate this developments and also for our current strategies are in that considers view included combined categories. annual a and impacts XXXX. of XX% our and anticipate pricing those finally, guidance further Guidance pressures of segment a reflects reflects relatively products tax And infusion HA neutral rate decline in and XX%. about expected tariffs deemphasis Other we explore Corporate a intravenous effective now
believe our will XXXX to consolidated financial expansion level, position our journey, similar to guidance that this While revenue this results segments deliver deliver the year we results enable that implies the actions will on term our margin that take margins XX%. reignite adjusted us mid- a includes profile margins EBITDA be in the to XXXX over a than consistent long gross our X to and strategic XX% financial of operating ultimately and on growth company we greater
please the Operator, questions. open line for
